The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849.
Steven R. Alberts
No relevant relationships to disclose
Gamini S. Soori
No relevant relationships to disclose
Qian Shi
No relevant relationships to disclose
Dennis A. Wigle
No relevant relationships to disclose
Robert P. Sticca
No relevant relationships to disclose
Robert Clell Miller
No relevant relationships to disclose
James L. Leenstra
No relevant relationships to disclose
Patrick J. Peller
No relevant relationships to disclose
Tsung-Teh Wu
No relevant relationships to disclose
Harry H. Yoon
No relevant relationships to disclose
Timothy F. Drevyanko
No relevant relationships to disclose
Stephen Ko
No relevant relationships to disclose
Bassam Ibrahim Mattar
No relevant relationships to disclose
Daniel A. Nikcevich
No relevant relationships to disclose
Robert J. Behrens
No relevant relationships to disclose
Maged F. Khalil
No relevant relationships to disclose
George P. Kim
No relevant relationships to disclose